clinical trials Archives

Comic-style illustration titled “The Fund-Raisers!” showing investors, a biotech innovation globe, a Forbion shield and laboratories, with a speech bubble announcing “2.6 billion raised.”

Forbion’s $2.6 Billion Biotech Raise Signals Smart Money Is Backing the Next Wave of Medicines -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. October 8, 2026 645Views 0Likes

Two new funds, institutional backing and a pharmaceutical heavyweight give the European life sciences investor fresh capital to turn promising science into investable businesses. Biotechnology has never suffered from a shortage of ambitious ideas. Financing them is another matter. Forbion has just…

Comic-style illustration of Michael J. Fox pointing toward Parkinson’s research and clinical trial displays, surrounded by scientists, patients and investors, with upward arrows symbolizing progress and investor optimism.

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

by John F. Heerdink, Jr. October 8, 2026 384Views 0Likes

Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles. The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…

Promotional graphic for Tribe Public’s CEO presentation and Q&A webinar, “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” featuring Serina Therapeutics CEO Steven Ledger; September 24, 2026, at 8:30 a.m. PT / 11:30 a.m. ET.

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

by John F. Heerdink, Jr. September 23, 2026 196Views 0Likes

Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…

Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026 307Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…

Tag: clinical trials

Forbion’s $2.6 Billion Biotech Raise Signals Smart Money Is Backing the Next Wave of Medicines -( $IBB $LLY $XBI )

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

Your Guide To Staying Informed In The Markets